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Background: The differential diagnosis between primary and secondary breast cancers might be difficult, especially
in poorly differentiated tumors. Thyroid Transcription Factor-1 (TTF-1) has been regarded as a reliable marker for
lung or thyroid origin, with only occasional positive staining in other tumors. However, positive cases have recently
been reported among primary breast carcinomas.
Methods and results: Here, we analyzed expression of TTF-1 protein (clone SPT24) by immunohistochemical
staining of sections from paraffin embedded tumor samples in 247 primary breast cancers from the population-
based Norwegian Breast Cancer Screening Program. Positive staining (weak or strong) was observed in 7 cases
(2,8%). As novel observations, positivity was demonstrated more frequently in estrogen receptor negative cases
(14,0% vs. 1,4%; p = 0,004), highly proliferative tumors (8,8% vs. 1,1%; p = 0,008), tumors with a basal-like phenotype
by showing expression of CK5/6 and/or P-cadherin (11,1% vs. 1,4%; p = 0,01), and tumors with blood vessel invasion
(9,7% vs. 1,9%; p = 0,04). Also, TTF-1 was associated with histological grade 3 tumors compared with grade 1 or 2
tumors (7,7% vs. 1,5%; p = 0,04) as well as lymph node positive cases (5,2% vs. 1,8%; p = 0,03).
Conclusions: Our population-based findings indicate that TTF-1 may be positive in approximately 3% of primary
breast cancers, and positivity indicates an association with adverse prognostic factors.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/8313753509421182
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Thyroid Transcription Factor-1(TTF-1), also known as
Nkx2.1 or thyroid-specific enhancer-binding protein,
regulates genes in the thyroid, lungs, and diencephalon
during embryogenesis [1,2]. Thus, TTF-1 has been
regarded as a reliable marker for tumors originating in
lung or thyroid tissues. TTF-1 is expressed in 72% of
adenocarcinomas of the lung [2] and can be a useful
marker in identifying lung tissue as a primary origin of
metastases, for instance to the breast. However, recent
studies have demonstrated that this marker might also
be positive in some neuroendocrine tumors of different
origins as well as in colorectal, gastric, endometrial,* Correspondence: tor.klingen@siv.no
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reproduction in any medium, provided the orendocervical, ovarian, prostatic, renal, and mesothelial
tumors [3-6].
Regarding primary breast cancer, some cases with
TTF-1 positivity have been reported [7-11] (Table 1).
We recently documented a case of breast cancer with
positive expression of TTF-1 [9], and we subsequently
wanted to establish the frequency of TTF-1 expression
in a population-based setting of breast cancer.Materials and methods
We carried out immunostaining for TTF-1 on paraffin
sections of 247 primary breast cancers selected from the
population-based Norwegian Breast Cancer Screening
Program. Vestfold County (Eastern Norway, 5% of the
Norwegian population with around 230,000 inhabitants)
was included in the Norwegian Breast Cancer Screeningl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Overview of studies reporting TTF-1 positive
primary breast cancers
Reference TTF-1
positiv/total
Study population TTF-1
clone
Ersahin et al., 1/1 Case study 8G7G3/1
Int J SurgPathol 2009
Christie et al., 1/1 Case study Unknown
IntJ Clin Exp Pathol 2010
Klingen et al., 1/1 Case study SPT24
DiagnPathol 2010
Robens et al., 13/546 Unselected SPT24
Am J SurgPathol 2010
Sakuray et al., 4/134 Unselected 8G7G3/1
Histopathol 2011
Present study 7/247 Population-based SPT24
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during the study period from 2004 to 2008; attendance
rate was 71% and 76% during the first two screening
rounds. During the first two rounds, 204 invasive
screen-detected cancers were reported, and 46 invasive
interval breast cancers following the prevalent and subse-
quent round were found. Three cases were excluded from
this series: one screen-detected cancer had no residual
tumor tissue for further investigation; one screen-detected
tumor was diagnosed as a malignant phyllodes tumor, and
one patient with interval cancer suffered from multiple
metastases at the time of diagnosis, and no biopsy or sur-
gery was therefore performed. Thus, a total of 247 invasive
carcinomas were available for this population-based study,
202 screen-detected and 45 interval cancers.
One representative paraffin embedded block from each
surgical specimen, including tumor tissue with adjacent
peritumoral tissue, was selected for immunohistochemical
staining with TTF-1. In 8 cases, preoperative tumour biop-
sies were selected for investigation because tumor tissue
in surgical specimens was too scanty after neoadjuvant
treatment for locally advanced breast cancers (6 cases) or
routine pathology investigation (2 cases).
Immunohistochemical analyses were performed by rou-
tine methods on 4-5 μm-thick, formalin fixed, paraffin-
embedded tissue sections. Briefly, after the slides were dried
for 20-60 minutes in a 60°C oven, they were placed on the
Ventana Benchmark automated immunostainer (Ventana
Medical Systems, Tucson, AZ) and dewaxed. Heat-induced
epitope retrieval was performed with Ventana`s CC1
retrieval solution for 30 minutes at 95°C to 100°C.
Primary antibody Thyroid transcription factor-1 (TTF-1),
clone SPT24 (Novocastra/Leica) at a 1:100 dilution,
mouse monoclonal antibody, was applied to the sections
at 37°C for 32 minutes. Presence of the antigen wasvisualized by using the Ultra View DAB detection kit
(Ventana).
TTF-1 positive cases were evaluated for intensity of
nuclear expression and expression area. A staining index
(values 0-9), obtained as a product of staining intensity
(0-3) and proportion of immunopositive tumor cells
(≤10% = 1, 10-50% = 2, >50% = 3), was calculated as pre-
viously published [12]. Staining index ≥6 was considered
to represent strong TTF-1 expression and a staining
index <6 was considered a weak TTF-1 expression.
Staining was recorded independently by three observers
(TK, YC and PS). In cases recorded with different obser-
ver evaluation, consensus was obtained after discussion
between all three observers. TTF-1 positive cases were
also evaluated by Anti-Thyroglobulin staining (clone
2H11 + 6E1, Roche).
The cases were divided into two groups according to
tumor size ≤ 2 cm or > 2 cm. Histological grade was
recorded according to the Nottingham criteria [13].
Nodal status was reported as negative for lymph nodes
without tumor or positive for one or more lymph nodes
with tumor spread. Tumor cells invading lymphatic or
blood vessels were examined on sections using D2-40
and CD31 as previously described [14]. Briefly, lymph-
atic vessel invasion (LVI) was recorded if tumor tissue
was located within more than one D2-40 positive vessel
structure, and blood vessel invasion (BVI) was reported
when tumor cells were detected in one or more CD31
positive and D2-40 negative vessels. Methods and evalu-
ation for Cytokeratin 5/6, P-cadherin, Ki67, estrogen re-
ceptor (ER), progesterone receptor (PR) and HER2 have
been described previously [15].
Data were analyzed using the Fisher`s exact test (2×2
contingency table). P-values of 0,05 or less were consi-
dered significant.
The study was approved by the Regional Committee
for Medical Research Ethics and protocols followed the
guidelines by the Helsinki Declaration.
Results
Among 247 primary breast cancer specimens in this study,
201 (81%) were invasive ductal carcinomas, 26 (11%) were
invasive lobular carcinomas and the remaining 20 cases
(8%) consisted of a variety of other types of breast carcin-
omas. 73 cases (30%) were grade 1, 122 (49%) grade 2 and
52 (21%) grade 3. We found 189 cases (77%) ≤2 cm and
58 cases (23%) > 2 cm. The median tumor diameter was
14 mm in the screening group and 15 mm in the interval
group. 77 cases (31%) had metastases to one or more
lymph nodes. 218 cases (88%) were estrogen receptor (ER)
positive (by 10% cut-off value of stained cells); 157 cases
(64%) were progesterone receptor positive. HER2 was
score 3+ in 21 (8.5%) of the cases; score 2+ was observed
in 20 cases (8%), including 2 with ISH amplification. In
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representing 15 (7,4%) of the screen-detected cancers and
8 (17,8%) of the interval tumors.
TTF-1 (clone SPT24) expression was seen in 7 of 247
cases (2,8%) in this material (Table 2). Positive staining
was shown in 6 surgical specimens and in one pre-
operative core needle biopsy (Figure 1). Three cases had a
high TTF-1 expression with a staining index of 9 (2 cases),
and 6 (1 case), while 4 cases had a low TTF-1 expression
with a staining index of 3 (1 case) and 2 (3 cases). There
were 6 surgical specimens with carcinoma in situ in the
periphery of invasive tumors, and 3 of these cases (#2, #4,
#6) had TTF-1 expression in the carcinoma in situ com-
ponent. Among the positive cases were six invasive ductal
carcinomas and one case of invasive lobular carcinoma
(#6). Follow-up time after tumor diagnosis for TTF-1 posi-
tive cases varied from 29-61 months, and one patient (#1)
died from breast cancer. Mean distance from tumors to
skin was 27 mm for TTF-1 positive cases. All 7 TTF-1
positive cases were negative for Anti-Thyroglobulin.
TTF-1 positivity was significantly more frequent with
ER negative cases (14% vs. 1,4%; p = 0,004), Ki-67 staining
by upper quartile (8,8% vs. 1,1%; p = 0,008), with CK 5/6
or P-cadherin positive cases (11,1% vs. 1,4%; p = 0,01),
with lymph node positive cancers (5,2% vs. 1,8%; p = 0,03),
with histological grade 3 tumors compared with grade
1 or 2 tumors (7,7% vs. 1,5%; p = 0,04), and with BVI
positive cases (9,7% vs. 1,9%; p = 0,04).
TTF-1 positive tumors tended to be more frequent
(although not significant) in interval cancers compared
with screening-detected cancers (6,7% vs. 2,0%; P = 0,12),
in PR negative tumors compared with PR positive tumors
(4,4% vs. 1,9%; p = 0,26), in HER2 positive tumors com-
pared to HER2 negative (4,8% vs. 2,7%; P = 0,47) and in
LVI positive cancers (4,8% vs. 2,2%; p = 0,37) compared to
LVI negative tumors.
Discussion
In this population-based study, TTF-1 expression was
found in 2,8% of the cases, almost the same frequency
(2,4%) as Robens et al. [7]. Both studies used the SPT24
clone, but in the study by Robens a different autostainer
(DAKO) was used on an unselected material with more
biopsies than surgical specimens. Sakuray et al. [8] found
4/134 (3,0%) cases with positivity for TTF-1 (clone
8G7G3/1) in a study using tissue microarrays. All these
three studies demonstrated similar frequencies of TTF-1
positivity (2-3%) despite some differences in clones and
technical conditions.
There are two commercially available clones for
monoclonal TTF-1 antibodies in immunohistological
use; SPT24 and 8G7G3/1. SPT24 has been suggested to
be more specific but less sensitive than 8G7G3/1 [16].
Reviewing previous literature indicates that TTF-1positive breast cancer has been demonstrated with both
clones (Table 1). Matoso et al. [17] found the same sensi-
tivity for SPT24 and 8G7G3/1 in non-pulmonary tumors,
under the same technical conditions for antigen retrieval
and detection system. However, the SPT24 clone has a
stronger nuclear staining and less non-specific cytoplasmic
staining than 8G7G3/1 [18]. This clone is recommended
by the Nordic Immunohistochemical Quality Control
(NordiQC) [19].
Both Robens et al. and our present study demon-
strated a significantly higher frequency of TTF-1 positiv-
ity in histological grade 3 tumors. As novel observations,
we here find significantly more TTF-1 positive tumors
with increased tumor cell proliferation (Ki67), a basal
like phenotype (CK5/6 and/or P-cadherin expression),
lymph node metastasis, ER negativity, and blood vessel
invasion. These findings suggest an association between ad-
verse prognostic factors and TTF-1 positivity in a small
subgroup of breast cancers.
In 2000, Perou and co-workers indentified five mo-
lecular subgroups of breast cancers (luminal A, luminal
B, normal breast-like, Her2 positive or basal-like) by use
of cDNA microarray and un-supervised cluster analysis
[20], and several studies have since addressed the immu-
nohistochemical surrogates to these subgroups [21]. The
basal-like subgroup has variable expressions of high
molecular-weight “basal” cytokeratins like CK5/6, CK14,
CK17, myoepithelial markers (smooth muscle actin and
p63), CD117, P-cadherin and EGFR [22]. Single markers
like CK5/6 and P-cadherin have been used previously
[23] and in the present study to define this subgroup.
Basal-like tumors are often hormone receptor low or
negative and Her2 negative (triple negative). Others have
used more strict criteria with a “core basal profile”: ER
negative, Her2 negative and CK5/6 and/or EGFR positive
to define these tumors [24]. Morphologically, basal-like
breast carcinomas are characterized by high histological
grade, increased mitotic counts, marked nuclear pleo-
morphism, the presence of necrotic areas, pushing bor-
ders, and often marked lymphocytic infiltration [21]. A
morphology with such basal-like features is demonstrated
in one of our TTF-1 positive cases (Figure 2).
Secondary tumors in the breast are uncommon, with a
reported frequency of 0,4-2% [25-27]. Studies [25,26,28]
have previously shown that pulmonary carcinoma, malig-
nant melanoma and lymphoma are the three most com-
mon secondary tumors. It could be argued that some of
our TTF-1 positive cases represent metastases from lung
cancer, but we regard this possibility as unlikely. First, six
of our cases have carcinoma in situ in the periphery of the
invasive tumor (except case #7). Second, in none of the
patients was the tumor close to the skin, as is typical for
metastases [19]. One patient (case #5) had a partially
rounded mass located 8mm from the skin; however,
Table 2 Clinico-pathological and radiological characteristics of patients with TTF-1 positive primary breast cancers
Patient
number
Sample
type
TTF-1
expression
(staining index)
Tumor
diameter
(mm)
Grade Tumor-
positive
lymph-nodes
ER PR Her2 CK 5/6
and/or
P-cadherin
Ki
67
(%)
Mode of
presentation
Mammo-
graphy
findings
Distance
from skin
(mm)
Follow-up time after
tumor diagnosis
(months)
Status
1 SS Weak (2) 27 3 1/12 - - + + 50,5 Screening Stellate opacity 47 29 DEAD
2 SS Strong (9) 15 1 0/3 + + - - 25,4 Interval Irregular
microlobulated
density
36 61 AW
3 SS Weak (3) 22 3 1/21 - - - + 41,2 Interval Diffuse density 30 38 AW
4 SS Weak (2) 9 2 1/11 + + - - 14,5 Screening Irregular
partially
rounded mass
8 60 AW
5 SS Weak (2) 21 3 1/14 - - - + 41,2 Screening Irregular density 18 49 AW
6 SS Strong (9) 17 2 1/8 + + - - 22,9 Screening Irregular density 33 54 AW
7 CNB Strong (6) 70 3 0/1 + - - + 55,4 Interval Lobulated mass
density
16 60 AW
SS, Surgical specimen; CNB, Core needle biopsy; ER, Estrogen receptor; PR, Progesterone receptor; DEAD, Dead of disease; AW, Alive and well.
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Figure 1 Breast carcinomas with strong (a, b) or weak (c)
nuclear expression of TTF1 (x400).
Figure 2 Basal-like morphology with marked nuclear
pleomorphism and lymphocytic infiltration in one TTF-1
positive breast carcinoma.
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carcinoma in situ and the fact that the patient survived
more than 5 years after diagnosis. Third, one of the cases
(case #6) showed typical features of lobular carcinoma,
which argues against pulmonary origin.
It can be challenging to differentiate a primary breast
carcinoma from a cancer metastasis. Pulmonary adenocar-
cinomas often demonstrate the same cytokeratin-profile
as breast carcinomas with CK7 positivity and CK20negativity. Also, pulmonary carcinomas can occasionally
stain positive for ER, PR, mammaglobin or gross cystic
disease protein [7,29-32]. Napsin A is a sensitive marker
for lung adenocarcinoma [33], and a combination of TTF-
1 and Napsin A may possibly be better than TTF-1 alone
in confirming or excluding lung metastases to the breast.
It is important that several markers are used in combin-
ation as a profile to differentiate between breast carcin-
omas and a metastatic lesion. Clinical and radiological
information is also important in achieving the correct
diagnosis. Information about known pulmonary tumors
should always be included on the pathology request form
as well as radiological information pertaining to breast le-
sions, such as morphology of the tumor and its distance
from the skin, which can all be of valuable help in the
diagnosis.
In conclusion, our population-based study indicates
that TTF-1 expression may be present in 3% of primary
breast cancers. In addition to previous observations,
our novel findings indicate that TTF-1 expression is
strongly associated with features of aggressive breast
cancer and adverse prognostic factors, such as estrogen
negativity, increased tumor cell proliferation, a basal-
like phenotype, blood vessel invasion and lymph node
positivity.Competing interests
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